oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis
Steno Diabetes Center, Gentofte, Denmark.
Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; Department of Psychiatry, McGill University, Montréal QC, Canada; Bipolar Disorders Clinic, Douglas Mental Health University Institute, Montréal QC, Canada.
Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; Department of Psychiatry, Helsinki University, Helsinki, Finland; Department of Psychiatry, Helsinki University Hospital, Helsinki, Finland.
Steno Diabetes Center, Gentofte, Denmark.
Vise andre og tillknytning
2016 (engelsk)Inngår i: Translational Psychiatry, ISSN 2158-3188, E-ISSN 2158-3188, Vol. 6, nr 11, artikkel-id e951Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. These metabolic co-morbidities are hypothesized to be related to both treatment side effects as well as to metabolic changes occurring during the psychosis. Earlier metabolomics studies have shown that blood metabolite levels are predictive of insulin resistance and type 2 diabetes in the general population as well as sensitive to the effects of antipsychotics. In this study, we aimed to identify the metabolite profiles predicting future weight gain and other metabolic abnormalities in psychotic patients. We applied comprehensive metabolomics to investigate serum metabolite profiles in a prospective study setting in 36 first-episode psychosis patients during the first year of the antipsychotic treatment and 19 controls. While corroborating several earlier findings when comparing cases and controls and the effects of the antipsychotic medication, we also found that prospective weight gain in psychotic patients was associated with increased levels of triacylglycerols with low carbon number and double-bond count at baseline, that is, lipids known to be associated with increased liver fat. Our study suggests that metabolite profiles may be used to identify the psychotic patients most vulnerable to develop metabolic co-morbidities, and may point to a pharmacological approach to counteract the antipsychotic-induced weight gain.

sted, utgiver, år, opplag, sider
London. United Kingdom: Nature Publishing Group, 2016. Vol. 6, nr 11, artikkel-id e951
HSV kategori
Forskningsprogram
Psykiatri
Identifikatorer
URN: urn:nbn:se:oru:diva-53599DOI: 10.1038/tp.2016.222ISI: 000392133200004PubMedID: 27845774OAI: oai:DiVA.org:oru-53599DiVA, id: diva2:1048638
Merknad

Funding Agency:

European Union  602478

Tilgjengelig fra: 2016-11-21 Laget: 2016-11-21 Sist oppdatert: 2018-07-17bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Hyötyläinen, Tuulia

Søk i DiVA

Av forfatter/redaktør
Hyötyläinen, Tuulia
Av organisasjonen
I samme tidsskrift
Translational Psychiatry

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 208 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf